EMA Application withdrawn: Enpaxiq — CTI Life Sciences Limited

View source ↗

Summary

The EMA withdrawn the application for Enpaxiq by CTI Life Sciences Limited, with the primary indication in myelofibrosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• Enpaxiq

Snippet

Status: Application withdrawn. Therapeutic area: Primary Myelofibrosis. MAH: CTI Life Sciences Limited. Decision date: 24/03/2017. Orphan medicine